

MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence
Report Generation Date: December 2, 2025
Data as of: December 2, 2020¹
Retention by Visit and Site

	Birmingham	Blantyre	Chiang Mai	Hillbrow, WRHI	Lima, San Miguel	Pittsburgh	San Francisco	All Sites
Participants Enrolled	33	31	30	30	30	33	30	217
Visit 3: Day 28/Week 4 - 1st PUEV								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	29 (88%)	30 (97%)	29 (97%)	27 (90%)	28 (97%)	30 (91%)	28 (93%)	201 (93%)
Not Completed	4 (12%)	1 (3%)	1 (3%)	3 (10%)	1 (3%)	3 (9%)	2 (7%)	15 (7%)
Missed	4 (12%)	0 (0%)	1 (3%)	3 (10%)	1 (3%)	3 (9%)	2 (7%)	14 (6%)
Terminated Early	0 (0%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)
Not Expected	0	0	0	0	0	0	0	0
Visit 4: Day 35/Week 5 - Product Switch Visit								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	26 (79%)	30 (97%)	27 (90%)	21 (70%)	29 (100%)	28 (85%)	24 (80%)	185 (86%)
Not Completed	7 (21%)	1 (3%)	3 (10%)	9 (30%)	0 (0%)	5 (15%)	6 (20%)	31 (14%)
Missed	5 (15%)	0 (0%)	3 (10%)	9 (30%)	0 (0%)	5 (15%)	6 (20%)	28 (13%)
Terminated Early	2 (6%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (1%)
Not Expected	0	0	0	0	0	0	0	0
Visit 5: Day 63/Week 9 - 2nd PUEV								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	27 (82%)	30 (97%)	29 (97%)	23 (77%)	23 (79%)	27 (82%)	21 (70%)	180 (83%)
Not Completed	6 (18%)	1 (3%)	1 (3%)	7 (23%)	6 (21%)	6 (18%)	9 (30%)	36 (17%)
Missed	3 (9%)	0 (0%)	1 (3%)	7 (23%)	6 (21%)	3 (9%)	9 (30%)	29 (13%)
Terminated Early	3 (9%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	3 (9%)	0 (0%)	7 (3%)
Not Expected	0	0	0	0	0	0	0	0
Visit 6: Day 70/Week 10 - Product Switch Visit								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	26 (79%)	30 (97%)	25 (83%)	20 (67%)	21 (72%)	23 (70%)	14 (47%)	159 (74%)
Not Completed	7 (21%)	1 (3%)	5 (17%)	10 (33%)	8 (28%)	10 (30%)	16 (53%)	57 (26%)
Missed	4 (12%)	0 (0%)	5 (17%)	10 (33%)	8 (28%)	7 (21%)	16 (53%)	50 (23%)
Terminated Early	3 (9%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	3 (9%)	0 (0%)	7 (3%)
Not Expected	0	0	0	0	0	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.

MTN 035 - Rectal Microbicide Acceptability, Tolerability, and Adherence
Report Generation Date: December 2, 2025
Data as of: December 2, 2020¹
Retention by Visit and Site

	Birmingham	Blantyre	Chiang Mai	Hillbrow, WRHI	Lima,San Miguel	Pittsburgh	San Francisco	All Sites
Visit 7: Day 98/Week 14 - 3rd PUEV								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	23 (70%)	29 (94%)	30 (100%)	21 (70%)	17 (59%)	26 (79%)	17 (57%)	163 (75%)
Not Completed	10 (30%)	2 (6%)	0 (0%)	9 (30%)	12 (41%)	7 (21%)	13 (43%)	53 (25%)
Missed	6 (18%)	1 (3%)	0 (0%)	9 (30%)	11 (38%)	4 (12%)	13 (43%)	44 (20%)
Terminated Early	4 (12%)	1 (3%)	0 (0%)	0 (0%)	1 (3%)	3 (9%)	0 (0%)	9 (4%)
Not Expected	0	0	0	0	0	0	0	0
Visit 8: Day 105/Week 15 - Final Termination								
Visit								
Expected ²	33	31	30	30	29	33	30	216
Completed ³	26 (79%)	26 (84%)	29 (97%)	19 (63%)	18 (62%)	26 (79%)	16 (53%)	160 (74%)
Not Completed	7 (21%)	5 (16%)	1 (3%)	11 (37%)	11 (38%)	7 (21%)	14 (47%)	56 (26%)
Missed	3 (9%)	4 (13%)	1 (3%)	10 (33%)	10 (34%)	4 (12%)	14 (47%)	46 (21%)
Terminated Early	4 (12%)	1 (3%)	0 (0%)	0 (0%)	1 (3%)	3 (9%)	0 (0%)	9 (4%)
Not Expected	0	0	0	0	0	0	0	0

¹ This report includes data received at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received at SCHARP.